Financial Instruments (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Fair Value Disclosures [Abstract] |
|
| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis |
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | As of December 31, 2025 | | As of December 31, 2024 | | (MILLIONS) | | Total | | Level 1 | | Level 2 | | Level 3 | | Total | | Level 1 | | Level 2 | | Level 3 | | Financial assets: | | | | | | | | | | | | | | | | | | Short-term investments | | | | | | | | | | | | | | | | | Equity securities with readily determinable fair value(a) | | $ | 2,596 | | | $ | — | | | $ | 2,596 | | | $ | — | | | $ | 7,848 | | | $ | 6,456 | | | $ | 1,392 | | | $ | — | | | | | | | | | | | | | | | | | | | | Available-for-sale debt securities: | | | | | | | | | | | | | | | | | | Government and agency—non-U.S. | | 4,859 | | | — | | | 4,859 | | | — | | | 6,855 | | | — | | | 6,855 | | | — | | | Government and agency—U.S. | | 3,030 | | | — | | | 3,030 | | | — | | | 2,853 | | | — | | | 2,853 | | | — | | | Corporate and other | | 1,294 | | | — | | | 1,294 | | | — | | | 1,173 | | | — | | | 1,173 | | | — | | | | 9,183 | | | — | | | 9,183 | | | — | | | 10,881 | | | — | | | 10,881 | | | — | | | Total short-term investments | | 11,779 | | | — | | | 11,779 | | | — | | | 18,729 | | | 6,456 | | | 12,273 | | | — | | | Other current assets | | | | | | | | | | | | | | | | | | Derivative assets: | | | | | | | | | | | | | | | | | | Interest rate contracts | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | Foreign exchange contracts | | 416 | | | — | | | 416 | | | — | | | 1,056 | | | — | | | 1,056 | | | — | | | Total other current assets | | 416 | | | — | | | 416 | | | — | | | 1,056 | | | — | | | 1,056 | | | — | | | Long-term investments | | | | | | | | | | | | | | | | | Equity securities with readily determinable fair values(b) | | 642 | | | 642 | | | — | | | — | | | 1,246 | | | 1,246 | | | — | | | — | | | | | | | | | | | | | | | | | | | | Available-for-sale debt securities: | | | | | | | | | | | | | | | | | | Government and agency—non-U.S. | | 1 | | | — | | | 1 | | | — | | | — | | | — | | | — | | | — | | | | | | | | | | | | | | | | | | | | Corporate and other | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | | 1 | | | — | | | 1 | | | — | | | — | | | — | | | — | | | — | | | Total long-term investments | | 642 | | | 642 | | | 1 | | | — | | | 1,246 | | | 1,246 | | | — | | | — | | | Other noncurrent assets | | | | | | | | | | | | | | | | | | Derivative assets: | | | | | | | | | | | | | | | | | | Interest rate contracts | | 52 | | | — | | | 52 | | | — | | | 13 | | | — | | | 13 | | | — | | | Foreign exchange contracts | | 64 | | | — | | | 64 | | | — | | | 447 | | | — | | | 447 | | | — | | | Total derivative assets | | 116 | | | — | | | 116 | | | — | | | 460 | | | — | | | 460 | | | — | | Insurance contracts(c) | | 999 | | | — | | | 999 | | | — | | | 875 | | | — | | | 875 | | | — | | | Total other noncurrent assets | | 1,115 | | | — | | | 1,115 | | | — | | | 1,335 | | | — | | | 1,335 | | | — | | | Total assets | | $ | 13,953 | | | $ | 642 | | | $ | 13,311 | | | $ | — | | | $ | 22,366 | | | $ | 7,701 | | | $ | 14,665 | | | $ | — | | | | | | | | | | | | | | | | | | | | Financial liabilities: | | | | | | | | | | | | | | | | | | Other current liabilities | | | | | | | | | | | | | | | | | | Derivative liabilities: | | | | | | | | | | | | | | | | | | Interest rate contracts | | $ | 16 | | | $ | — | | | $ | 16 | | | $ | — | | | $ | 28 | | | $ | — | | | $ | 28 | | | $ | — | | | Foreign exchange contracts | | 412 | | | — | | | 412 | | | — | | | 217 | | | — | | | 217 | | | — | | Contingent consideration liabilities(d) | | 95 | | | — | | | — | | | 95 | | | 39 | | | — | | | — | | | 39 | | | Total other current liabilities | | 523 | | | — | | | 428 | | | 95 | | | 284 | | | — | | | 245 | | | 39 | | | Other noncurrent liabilities | | | | | | | | | | | | | | | | | | Derivative liabilities: | | | | | | | | | | | | | | | | | | Interest rate contracts | | 215 | | | — | | | 215 | | | — | | | 397 | | | — | | | 397 | | | — | | | Foreign exchange contracts | | 815 | | | — | | | 815 | | | — | | | 723 | | | — | | | 723 | | | — | | Contingent consideration liabilities(d) | | 1,695 | | | — | | | — | | | 1,695 | | | 477 | | | — | | | — | | | 477 | | | Total other noncurrent liabilities | | 2,725 | | | — | | | 1,030 | | | 1,695 | | | 1,598 | | | — | | | 1,121 | | | 477 | | | Total liabilities | | $ | 3,248 | | | $ | — | | | $ | 1,458 | | | $ | 1,790 | | | $ | 1,882 | | | $ | — | | | $ | 1,366 | | | $ | 517 | |
(a)Includes money market funds primarily invested in U.S. Treasury and government debt. As of December 31, 2024, short-term equity securities included our previous investment in Haleon of $6.5 billion. In the first quarter of 2025, we sold the remaining portion of our investment in Haleon for $6.3 billion. See Note 2C. (b)Long-term equity securities of $146 million as of December 31, 2025 and $133 million as of December 31, 2024 were held in restricted trusts for U.S. non-qualified employee benefit plans. (c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions—net (see Note 4). (d)Includes the fair value of contingent consideration associated with the acquisition of Metsera and certain prior business combinations. Fair value is estimated by using a probability-weighted discounted cash flow approach (see Note 16D).
|
| Schedule of Changes in Contingent Consideration Liabilities |
| | | | | | | | | | | | | The following provides the changes in our contingent consideration liabilities valued using significant unobservable inputs: | | Year Ended December 31, | | (MILLIONS) | 2025 | | 2024 | | Fair value, beginning | $ | 517 | | | $ | 692 | | Changes in estimated fair value(a) | 67 | | | (52) | | Additions | 1,266 | | | — | | Payments | (59) | | | (123) | | | Transfer into/(out of) Level 3 | — | | | — | | | | | | | Fair value, ending | $ | 1,790 | | | $ | 517 | |
(a)Reported in Other (income)/deductions––net. See Note 4.
|
| Summary of Investments |
| | | | | | | | | | | | | | | | The following summarizes our investments by classification type: | | | As of December 31, | | (MILLIONS) | | 2025 | | 2024 | | Short-term investments | | | | | Equity securities with readily determinable fair values | | $ | 2,596 | | | $ | 7,848 | | | Available-for-sale debt securities | | 9,183 | | | 10,881 | | | Held-to-maturity debt securities | | 675 | | | 705 | | | Total Short-term investments | | $ | 12,454 | | | $ | 19,434 | | | | | | | | Long-term investments | | | | | Equity securities with readily determinable fair values(a) | | $ | 642 | | | $ | 1,246 | | | Available-for-sale debt securities | | 1 | | | — | | | Held-to-maturity debt securities | | 48 | | | 45 | | Private equity securities at cost(a) | | 696 | | | 719 | | Equity-method investments | | 235 | | | 217 | | Total Long-term investments | | $ | 1,621 | | | $ | 2,228 | | | | | | | | | | | | | | | | |
(a)Represent investments in the life sciences sector.
|
| Contractual Maturities of Available-for-sale and Held-to-maturity Securities |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions: | | | As of December 31, 2025 | As of December 31, 2024 | | | | | Gross Unrealized | | | | Maturities (in Years) | | | Gross Unrealized | | | | (MILLIONS) | | Amortized Cost | | Gains | | Losses | | Fair Value | | Within 1 | | Over 1 to 5 | | Over 5 | | Amortized Cost | | Gains | | Losses | | Fair Value | | Available-for-sale debt securities | | | | | | | | | | | | | | | | | | | | | | | Government and agency––non-U.S. | | $ | 4,890 | | | $ | 3 | | | $ | (34) | | | $ | 4,859 | | | $ | 4,859 | | | $ | 1 | | | $ | — | | | $ | 6,970 | | | $ | 8 | | | $ | (123) | | | $ | 6,855 | | Government and agency––U.S. | | 3,030 | | | — | | | — | | | 3,030 | | | 3,030 | | | — | | | — | | | 2,853 | | | — | | | — | | | 2,853 | | | Corporate and other | | 1,295 | | | — | | | (1) | | | 1,294 | | | 1,294 | | | — | | | — | | | 1,179 | | | — | | | (6) | | | 1,173 | | Held-to-maturity debt securities | | | | | | | | | | | | | | | | | | | | | | | Time deposits and other | | 487 | | | — | | | — | | | 487 | | | 444 | | | 7 | | | 36 | | | 697 | | | — | | | — | | | 697 | | Government and agency––non-U.S. | | 236 | | | — | | | — | | | 236 | | | 231 | | | 4 | | | 1 | | | 237 | | | — | | | — | | | 237 | | | Total debt securities | | $ | 9,938 | | | $ | 3 | | | $ | (35) | | | $ | 9,906 | | | $ | 9,858 | | | $ | 12 | | | $ | 37 | | | $ | 11,935 | | | $ | 8 | | | $ | (129) | | | $ | 11,814 | |
|
| Schedule of Available-for-sale Securities Reconciliation |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions: | | | As of December 31, 2025 | As of December 31, 2024 | | | | | Gross Unrealized | | | | Maturities (in Years) | | | Gross Unrealized | | | | (MILLIONS) | | Amortized Cost | | Gains | | Losses | | Fair Value | | Within 1 | | Over 1 to 5 | | Over 5 | | Amortized Cost | | Gains | | Losses | | Fair Value | | Available-for-sale debt securities | | | | | | | | | | | | | | | | | | | | | | | Government and agency––non-U.S. | | $ | 4,890 | | | $ | 3 | | | $ | (34) | | | $ | 4,859 | | | $ | 4,859 | | | $ | 1 | | | $ | — | | | $ | 6,970 | | | $ | 8 | | | $ | (123) | | | $ | 6,855 | | Government and agency––U.S. | | 3,030 | | | — | | | — | | | 3,030 | | | 3,030 | | | — | | | — | | | 2,853 | | | — | | | — | | | 2,853 | | | Corporate and other | | 1,295 | | | — | | | (1) | | | 1,294 | | | 1,294 | | | — | | | — | | | 1,179 | | | — | | | (6) | | | 1,173 | | Held-to-maturity debt securities | | | | | | | | | | | | | | | | | | | | | | | Time deposits and other | | 487 | | | — | | | — | | | 487 | | | 444 | | | 7 | | | 36 | | | 697 | | | — | | | — | | | 697 | | Government and agency––non-U.S. | | 236 | | | — | | | — | | | 236 | | | 231 | | | 4 | | | 1 | | | 237 | | | — | | | — | | | 237 | | | Total debt securities | | $ | 9,938 | | | $ | 3 | | | $ | (35) | | | $ | 9,906 | | | $ | 9,858 | | | $ | 12 | | | $ | 37 | | | $ | 11,935 | | | $ | 8 | | | $ | (129) | | | $ | 11,814 | |
|
| Held-to-maturity Securities |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions: | | | As of December 31, 2025 | As of December 31, 2024 | | | | | Gross Unrealized | | | | Maturities (in Years) | | | Gross Unrealized | | | | (MILLIONS) | | Amortized Cost | | Gains | | Losses | | Fair Value | | Within 1 | | Over 1 to 5 | | Over 5 | | Amortized Cost | | Gains | | Losses | | Fair Value | | Available-for-sale debt securities | | | | | | | | | | | | | | | | | | | | | | | Government and agency––non-U.S. | | $ | 4,890 | | | $ | 3 | | | $ | (34) | | | $ | 4,859 | | | $ | 4,859 | | | $ | 1 | | | $ | — | | | $ | 6,970 | | | $ | 8 | | | $ | (123) | | | $ | 6,855 | | Government and agency––U.S. | | 3,030 | | | — | | | — | | | 3,030 | | | 3,030 | | | — | | | — | | | 2,853 | | | — | | | — | | | 2,853 | | | Corporate and other | | 1,295 | | | — | | | (1) | | | 1,294 | | | 1,294 | | | — | | | — | | | 1,179 | | | — | | | (6) | | | 1,173 | | Held-to-maturity debt securities | | | | | | | | | | | | | | | | | | | | | | | Time deposits and other | | 487 | | | — | | | — | | | 487 | | | 444 | | | 7 | | | 36 | | | 697 | | | — | | | — | | | 697 | | Government and agency––non-U.S. | | 236 | | | — | | | — | | | 236 | | | 231 | | | 4 | | | 1 | | | 237 | | | — | | | — | | | 237 | | | Total debt securities | | $ | 9,938 | | | $ | 3 | | | $ | (35) | | | $ | 9,906 | | | $ | 9,858 | | | $ | 12 | | | $ | 37 | | | $ | 11,935 | | | $ | 8 | | | $ | (129) | | | $ | 11,814 | |
|
| Schedule of Gains and Losses on Investment Securities |
| | | | | | | | | | | | | | | | | | | | | | The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date: | | | Year Ended December 31, | | (MILLIONS) | | 2025 | | 2024 | | 2023 | Net (gains)/losses recognized during the period on equity securities(a) | | $ | 67 | | | $ | (1,008) | | | $ | (1,590) | | | Less: Net (gains)/losses recognized during the period on equity securities sold during the period | | 35 | | | (1,122) | | | (1,754) | | Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date | | $ | 32 | | | $ | 114 | | | $ | 165 | |
(a)Reported in Other (income)/deductions––net. See Note 4. Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of December 31, 2025, there were cumulative impairments and downward adjustments of $433 million and upward adjustments of $225 million. Impairments, downward and upward adjustments were not material to our operations in 2025, 2024 and 2023.
|
| Schedule of Short-term Borrowings |
| | | | | | | | | | | | | | | | Short-term borrowings include: | | | As of December 31, | | (MILLIONS) | | 2025 | | 2024 | Commercial paper, principal amount(a) | | $ | — | | | $ | 2,453 | | | Current portion of long-term debt, principal amount | | 3,000 | | | 3,750 | | Other short-term borrowings, principal amount(b) | | 157 | | | 755 | | Total short-term borrowings, principal amount | | 3,157 | | | 6,957 | | | | | | | | Net unamortized discounts, premiums and debt issuance costs | | (3) | | | (12) | | Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted | | $ | 3,154 | | | $ | 6,946 | |
(a)The weighted-average effective interest rate on commercial paper outstanding was approximately 4.94% as of December 31, 2024. (b)Primarily includes cash collateral. See Note 7F.
|
| Schedule of Long-term Debt Instruments |
| | | | | | | | | | | | | | | The following outlines our senior unsecured long-term debt(a) and the weighted-average stated interest rate by maturity: | | | As of December 31, | | (MILLIONS) | | 2025 | | 2024 | Notes due 2026 (3.7% for 2024)(b) | | $ | — | | | $ | 6,000 | | Notes due 2027 (2.9% for 2025 and 2.2% for 2024) | | 2,081 | | | 980 | | Notes due 2027 (Secured Overnight Financing Rate “SOFR” +0.500%) | | 500 | | | — | | Notes due 2028 (4.6% for 2025 and 2024) | | 5,660 | | | 5,660 | | Notes due 2029 (3.3% for 2025 and 3.5% for 2024) | | 2,631 | | | 1,750 | | Notes due 2030 (3.7% for 2025 and 3.6% for 2024) | | 6,250 | | | 5,250 | | Notes due 2031-2035 (4.4% for 2025 and 4.5% for 2024) | | 10,424 | | | 6,750 | | Notes due 2036-2040 (5.3% for 2025 and 5.4% for 2024) | | 10,458 | | | 9,534 | | Notes due 2041-2045 (4.3% for 2025 and 2024) | | 7,540 | | | 6,474 | | Notes due 2046-2050 (3.7% for 2025 and 2024) | | 4,750 | | | 4,750 | | Notes due 2051-2065 (5.3% for 2025 and 2024) | | 11,000 | | | 10,000 | | | Total long-term debt, principal amount | | 61,293 | | | 57,147 | | | Net fair value adjustments related to hedging and purchase accounting | | 834 | | | 701 | | | Net unamortized discounts, premiums and debt issuance costs | | (486) | | | (444) | | | | | | | | Total long-term debt, carried at historical proceeds, as adjusted | | $ | 61,641 | | | $ | 57,405 | | Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (3.9% for 2025 and 2024)) | | $ | 2,997 | | | $ | 3,747 | |
(a)Our long-term debt is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest. (b)Reclassified to the current portion of long-term debt. Issuances | | | | | | | | | | | | | | | | | | | | | | | | In 2025, we issued the following senior unsecured notes(a) : | | | (MILLIONS) | | | | | | Principal | | | Coupon Rate | | Maturity Date | | Issue Currency | | As of December 31, 2025 | | SOFR +0.500% | | November 15, 2027 | | U.S. dollar | | $ | 500 | | | | 3.875% | | November 15, 2027 | | U.S. dollar | | 1,000 | | | | 4.200% | | November 15, 2030 | | U.S. dollar | | 1,000 | | | | 4.500% | | November 15, 2032 | | U.S. dollar | | 1,250 | | | | 4.875% | | November 15, 2035 | | U.S. dollar | | 1,250 | | | | 5.600% | | November 15, 2055 | | U.S. dollar | | 500 | | | | 5.700% | | November 15, 2065 | | U.S. dollar | | 500 | | | | | | | | | $ | 6,000 | | (b) | | | | | | | | | | 2.875% | | May 19, 2029 | | Euro | | € | 750 | | | | 3.250% | | May 19, 2032 | | Euro | | 1,000 | | | | 3.875% | | May 19, 2037 | | Euro | | 750 | | | | 4.250% | | May 19, 2045 | | Euro | | 800 | | | | | | | | | € | 3,300 | | (c) |
(a)The fixed rate notes may be redeemed by us at any time, in whole, or in part, at a make-whole redemption price plus accrued and unpaid interest. (b)The net proceeds from the sale of the notes were used for general corporate purposes, including the acquisition of Metsera and the refinancing of existing indebtedness. The weighted average effective interest rate for the notes at issuance was 4.583%. (c)Issued through our wholly-owned finance subsidiary, PNIF, for general corporate purposes. The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PNIF has no assets or operations and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future. The weighted average effective interest rate for the notes at issuance was 3.605%.
|
| Schedule of Derivative Financial Instruments |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following summarizes the fair value of the derivative financial instruments and notional amounts: | | (MILLIONS) | | As of December 31, 2025 | | As of December 31, 2024 | | | | | Fair Value | | | | Fair Value | | | Notional | | Asset | | Liability | | Notional | | Asset | | Liability | | Derivatives designated as hedging instruments: | | | | | | | | | | | | | Foreign exchange contracts(a) | | $ | 22,984 | | | $ | 325 | | | $ | 1,066 | | | $ | 23,991 | | | $ | 1,250 | | | $ | 719 | | Interest rate contracts | | 6,750 | | | 52 | | | 230 | | | 6,750 | | | 13 | | | 425 | | | | | | 377 | | | 1,296 | | | | | 1,263 | | | 1,144 | | | | | | | | | | | | | | | | Derivatives not designated as hedging instruments: | | | | | | | | | | | | | Foreign exchange contracts | | $ | 22,777 | | | 155 | | | 162 | | | $ | 26,335 | | | 253 | | | 221 | | | | | | | | | | | | | | | | Total | | | | $ | 532 | | | $ | 1,458 | | | | | $ | 1,516 | | | $ | 1,366 | |
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2025 and $5.0 billion as of December 31, 2024.
|
| Schedule of Derivative Assets at Fair Value |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following summarizes the fair value of the derivative financial instruments and notional amounts: | | (MILLIONS) | | As of December 31, 2025 | | As of December 31, 2024 | | | | | Fair Value | | | | Fair Value | | | Notional | | Asset | | Liability | | Notional | | Asset | | Liability | | Derivatives designated as hedging instruments: | | | | | | | | | | | | | Foreign exchange contracts(a) | | $ | 22,984 | | | $ | 325 | | | $ | 1,066 | | | $ | 23,991 | | | $ | 1,250 | | | $ | 719 | | Interest rate contracts | | 6,750 | | | 52 | | | 230 | | | 6,750 | | | 13 | | | 425 | | | | | | 377 | | | 1,296 | | | | | 1,263 | | | 1,144 | | | | | | | | | | | | | | | | Derivatives not designated as hedging instruments: | | | | | | | | | | | | | Foreign exchange contracts | | $ | 22,777 | | | 155 | | | 162 | | | $ | 26,335 | | | 253 | | | 221 | | | | | | | | | | | | | | | | Total | | | | $ | 532 | | | $ | 1,458 | | | | | $ | 1,516 | | | $ | 1,366 | |
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2025 and $5.0 billion as of December 31, 2024.
|
| Schedule of Derivative Liabilities at Fair Value |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following summarizes the fair value of the derivative financial instruments and notional amounts: | | (MILLIONS) | | As of December 31, 2025 | | As of December 31, 2024 | | | | | Fair Value | | | | Fair Value | | | Notional | | Asset | | Liability | | Notional | | Asset | | Liability | | Derivatives designated as hedging instruments: | | | | | | | | | | | | | Foreign exchange contracts(a) | | $ | 22,984 | | | $ | 325 | | | $ | 1,066 | | | $ | 23,991 | | | $ | 1,250 | | | $ | 719 | | Interest rate contracts | | 6,750 | | | 52 | | | 230 | | | 6,750 | | | 13 | | | 425 | | | | | | 377 | | | 1,296 | | | | | 1,263 | | | 1,144 | | | | | | | | | | | | | | | | Derivatives not designated as hedging instruments: | | | | | | | | | | | | | Foreign exchange contracts | | $ | 22,777 | | | 155 | | | 162 | | | $ | 26,335 | | | 253 | | | 221 | | | | | | | | | | | | | | | | Total | | | | $ | 532 | | | $ | 1,458 | | | | | $ | 1,516 | | | $ | 1,366 | |
(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $5.0 billion as of December 31, 2025 and $5.0 billion as of December 31, 2024.
|
| Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures: | | | | Gains/(Losses) Recognized in OID(a) | | Gains/(Losses) Recognized in OCI(a) | | Gains/(Losses) Reclassified from OCI into OID and COS(a) | | | Year Ended December 31, | | (MILLIONS) | | 2025 | | 2024 | | 2025 | | 2024 | | 2025 | | 2024 | Derivative Financial Instruments in Cash Flow Hedge Relationships: | | | | | | | | | | | | | | Interest rate contracts | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | | $ | — | | Foreign exchange contracts(b) | | — | | | — | | | (270) | | | 466 | | | 211 | | | 124 | | Amount excluded from effectiveness testing and amortized into earnings(c) | | — | | | — | | | 58 | | | 34 | | | 57 | | | 34 | | | | | | | | | | | | | | | Derivative Financial Instruments in Fair Value Hedge Relationships: | | | | | | | | | | | | | | Interest rate contracts | | 221 | | | (253) | | | — | | | — | | | — | | | — | | | Hedged item | | (221) | | | 253 | | | — | | | — | | | — | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Derivative Financial Instruments in Net Investment Hedge Relationships: | | | | | | | | | | | | | | Foreign exchange contracts | | — | | | — | | | (1,361) | | | 498 | | | — | | | — | | Amount excluded from effectiveness testing and amortized into earnings(c) | | — | | | — | | | 321 | | | 119 | | | 207 | | | 154 | | | | | | | | | | | | | | | Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d): | | | | | | | | | | | | | | | | | | | | | | | | | | | Foreign currency long-term debt | | — | | | — | | | (101) | | | 49 | | | — | | | — | | | | | | | | | | | | | | | Derivative Financial Instruments Not Designated as Hedges: | | | | | | | | | | | | | | Foreign exchange contracts | | 98 | | | 50 | | | — | | | — | | | — | | | — | | | | | | | | | | | | | | | | | $ | 98 | | | $ | 50 | | | $ | (1,353) | | | $ | 1,166 | | | $ | 476 | | | $ | 313 | |
(a)OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income/(loss). (b)The amounts reclassified from OCI into COS were a net gain of $49 million in 2025 and a net gain of $119 million in 2024. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $16 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 17 years and relates to foreign currency debt. (c)The amounts reclassified from OCI were reclassified into OID. (d)Long-term debt includes foreign currency borrowings which are used in net investment hedges; the related carrying values as of December 31, 2025 and December 31, 2024 were $879 million and $777 million, respectively.
|
| Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges: | | | As of December 31, 2025 | | As of December 31, 2024 | | | | | Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount | | | | Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount | | (MILLIONS) | | Carrying Amount of Hedged Assets/Liabilities(a) | | Active Hedging Relationships | | Discontinued Hedging Relationships | | Carrying Amount of Hedged Assets/Liabilities(a) | | Active Hedging Relationships | | Discontinued Hedging Relationships | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Long-term debt | | $ | 7,110 | | | $ | (163) | | | $ | 821 | | | $ | 7,154 | | | $ | (384) | | | $ | 891 | |
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
|
| Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges: | | | As of December 31, 2025 | | As of December 31, 2024 | | | | | Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount | | | | Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount | | (MILLIONS) | | Carrying Amount of Hedged Assets/Liabilities(a) | | Active Hedging Relationships | | Discontinued Hedging Relationships | | Carrying Amount of Hedged Assets/Liabilities(a) | | Active Hedging Relationships | | Discontinued Hedging Relationships | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Long-term debt | | $ | 7,110 | | | $ | (163) | | | $ | 821 | | | $ | 7,154 | | | $ | (384) | | | $ | 891 | |
(a)Carrying amounts exclude the cumulative amount of fair value hedging adjustments.
|